



April 27, 2007

Nektar Executives Participating In Upcoming Investor Conferences

New Pulmonary Business Unit Head and Lead Business Development And Marketing Executive to Represent Nektar

SAN CARLOS, Calif., Apr 27, 2007 (BUSINESS WIRE) -- Senior executives of Nektar Therapeutics (Nasdaq: NKTR) are scheduled to participate in two upcoming investor conferences:

-- Deutsche Bank 2007 Health Care Conference, Wednesday, May 2, 2007, 1:00 pm Eastern Time (ET), Mayflower Hotel, Washington, D.C.; and,

-- Morgan Stanley Healthcare Unplugged Conference, Thursday, May 3, 2007, 1:30 pm ET, The Ritz-Carlton, Key Biscayne, Florida.

Presenting on behalf of Nektar Therapeutics are:

-- Nevan Elam, SVP, Head of Pulmonary Business Unit

Nevan Elam joined Nektar in January 2005 as Senior Vice President, Corporate Operations and General Counsel. In this role he ran one of Nektar's strategic business units as well as all legal affairs of the company. Previously, Elam was Chief Financial Officer of E2open, Inc., a technology corporation with operations in six countries. Elam was initially responsible for corporate and business development before he became E2open's Chief Financial Officer and ran the company's infrastructure including finance, legal, human resources and facilities. Prior to his management roles at E2open, Elam was a corporate partner in the law firm of Wilson Sonsini Goodrich & Rosati, where he represented corporations in the life sciences as well as emerging growth companies in other industries. Mr. Elam earned his J.D. degree from Harvard Law School and B.A. from Howard University.

-- Hoyoung Huh, M.D., Ph.D, SVP, Business Development and Marketing

Hoyoung Huh, Senior Vice President, Business Development and Marketing, joined the company in March 2005. A member of the Nektar Executive Committee, Dr. Huh leads major commercial functions for the company, including business development, alliance management, new product planning, and product and corporate marketing. He also heads key alliances for Nektar and is chairman of the Exubera Joint Development and Commercialization Committee with Pfizer. He is a frequent speaker on topics of licensing strategy, portfolio management and biotechnology commercialization. Previously, Dr. Huh was a partner at McKinsey and Company focusing on licensing, mergers and acquisitions, and product launch challenges and opportunities in the global biopharmaceutical industry. He currently serves on the Board of BayBio, a biotechnology industry association. Dr. Huh holds an M.D. from Cornell University, a Ph.D. in Genetics/Cell Biology from the Cornell University/Sloan Kettering Institute, and an A.B. in Biochemistry from Dartmouth College.

Nektar Therapeutics applies its industry leading pulmonary and PEGylation technology platforms to develop novel therapeutics and to improve the safety, efficacy and compliance of medicines already on the market.

SOURCE: Nektar Therapeutics

Nektar Therapeutics
Tim Warner, 650-283-4915
twarner@nektar.com

or
Stephan Herrera, 415-488-7699
sherrera@nektar.com

Copyright Business Wire 2007

News Provided by COMTEX